Consideration of Surrogate Endpoints for Overall Survival Associated With First-Line Immunotherapy in Extensive-Stage Small Cell Lung Cancer

Consideration of Surrogate Endpoints for Overall Survival Associated With First-Line Immunotherapy in Extensive-Stage Small Cell Lung Cancer

BackgroundThe combination of immune checkpoint inhibitors (ICIs) and chemotherapy is known to improve overall survival (OS) in patients with extensive-stage small cell lung cancer (ES-SCLC). ICIs have different response patterns and survival kinetics characteristics from those of the traditional che...

Full description

Bibliographic Details
Main Authors: Shuang Zhang, Shuang Li, Yanan Cui, Peiyan Zhao, Xiaodan Sun, Ying Cheng
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Oncology
Subjects:
small-cell lung cancer
surrogate endpoints
survival
immunotherapy
restricted mean survival time (RMST)
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.696010/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.696010/full

Similar Items